Utah Medical Products, Inc. (UTMD) Key Metrics
UTMD valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $236.5M
- Enterprise value
- $151.6M
- P/E (TTM)
- 22.7 10-yr median 22.4
- Forward P/E
- 13.0
- PEG ratio
- 4.25
- Price / sales
- 6.5 10-yr median 7.2
- Price / book
- 2.0 10-yr median 3.3
- EV / EBITDA
- 11.9 10-yr median 11.8
- Dividend yield
- 1.66% $1.24 a year
- Beta
- 0.39
UTMD key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsUTMD valuation Price multiples at each fiscal year-end price.
UTMD returns How much profit the business earns on the capital it uses.
UTMD per-share figures Results divided by the shares outstanding at year-end.
UTMD financial health Debt, liquidity and how easily interest is covered.
UTMD efficiency & capital use Working capital cycle and where the cash goes.
UTMD valuation history
UTMD returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
UTMD debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
UTMD cash returned to shareholders
UTMD price vs earnings per share
UTMD key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $181.3M | $215.3M | $306.3M | $366.2M | $366.0M | $309.5M | $403.4M | $311.4M | $304.2M | $274.0M |
| Enterprise value | $95.8M | $132.7M | $213.7M | $291.5M | $305.4M | $258.3M | $361.0M | $260.3M | $264.2M | $247.6M |
| P/E ratio | 16.1 | 15.5 | 18.4 | 22.2 | 24.7 | 28.7 | 27.4 | 16.8 | 35.8 | 22.6 |
| Price / sales | 4.7 | 5.3 | 6.1 | 7.0 | 7.5 | 7.3 | 8.6 | 7.4 | 7.3 | 7.0 |
| Price / book | 1.5 | 1.8 | 2.4 | 3.2 | 3.4 | 3.0 | 4.0 | 3.5 | 3.9 | 4.0 |
| Price / free cash flow | 12.7 | 14.8 | 14.2 | 18.0 | 17.7 | 16.1 | — | 18.9 | 19.9 | 24.4 |
| Price / operating cash flow | 12.3 | 14.5 | 13.7 | 17.3 | 17.3 | 15.4 | 23.7 | 18.5 | 18.0 | 18.9 |
| EV / sales | 2.5 | 3.2 | 4.3 | 5.6 | 6.2 | 6.1 | 7.7 | 6.2 | 6.4 | 6.3 |
| EV / EBITDA | 5.6 | 6.8 | 8.6 | 10.5 | 11.6 | 12.3 | 14.7 | 12.0 | 12.1 | 13.0 |
| EV / free cash flow | 6.7 | 9.1 | 9.9 | 14.3 | 14.8 | 13.4 | — | 15.8 | 17.3 | 22.1 |
| Earnings yield | 6.2% | 6.4% | 5.4% | 4.5% | 4.0% | 3.5% | 3.7% | 6.0% | 2.8% | 4.4% |
| Free cash flow yield | 7.9% | 6.8% | 7.1% | 5.6% | 5.6% | 6.2% | −1.1% | 5.3% | 5.0% | 4.1% |
| Dividend yield | 2.2% | 2.0% | 1.4% | 0.9% | 3.1% | 1.3% | 1.0% | 1.3% | 1.0% | 1.4% |
| Shareholder yield (dividends + buybacks) | 6.8% | 11.3% | 2.2% | 1.5% | 5.0% | 3.6% | 1.1% | 1.7% | 1.9% | 2.5% |
| Share price at fiscal year-end | $55.96 | $61.47 | $84.22 | $100.53 | $100.00 | $84.30 | $107.90 | $83.08 | $81.40 | $72.75 |
| Per share | ||||||||||
| Revenue per share | $11.89 | $11.68 | $13.81 | $14.35 | $13.40 | $11.49 | $12.54 | $11.21 | $11.08 | $10.43 |
| Earnings per share | $3.48 | $3.96 | $4.57 | $4.52 | $4.04 | $2.94 | $3.94 | $4.95 | $2.28 | $3.22 |
| Operating cash flow per share | $4.53 | $4.23 | $6.13 | $5.80 | $5.79 | $5.48 | $4.56 | $4.49 | $4.52 | $3.86 |
| Free cash flow per share | $4.42 | $4.17 | $5.95 | $5.58 | $5.64 | $5.25 | −$1.20 | $4.38 | $4.10 | $2.98 |
| Cash per share | $26.47 | $23.69 | $25.53 | $20.60 | $16.66 | $14.05 | $11.44 | $13.64 | $10.69 | $7.00 |
| Book value per share | $36.81 | $33.52 | $35.28 | $31.36 | $29.27 | $28.00 | $27.04 | $23.74 | $20.91 | $18.38 |
| Tangible book value per share | $32.21 | $28.83 | $30.16 | $24.85 | $20.57 | $17.61 | $15.22 | $16.14 | $12.36 | $9.95 |
| Dividends per share | $1.23 | $1.22 | $1.18 | $0.87 | $3.13 | $1.12 | $1.10 | $1.07 | $0.79 | $1.04 |
| Capex per share | $0.11 | $0.07 | $0.18 | $0.22 | $0.15 | $0.23 | $5.76 | $0.11 | $0.43 | $0.88 |
| Debt per share | $0.07 | $0.10 | $0.08 | $0.09 | $0.11 | $0.09 | $0.10 | — | $0.00 | $0.00 |
| Shares outstanding | 3.2M | 3.5M | 3.6M | 3.6M | 3.7M | 3.7M | 3.7M | 3.7M | 3.7M | 3.8M |
| Change in shares outstanding | −7.5% | −3.7% | −0.2% | −0.5% | −0.3% | −1.8% | −0.2% | +0.3% | −0.8% | −0.1% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 9.5% | 11.3% | 13.7% | 14.9% | 14.1% | 10.6% | 15.5% | 22.2% | 11.5% | 17.5% |
| Return on invested capital (ROIC) | 26.6% | 31.8% | 36.9% | 36.7% | 29.9% | 19.4% | 30.1% | 46.9% | 23.5% | 26.8% |
| Return on assets (ROA) | 9.2% | 10.8% | 12.8% | 13.8% | 13.0% | 9.7% | 14.1% | 19.3% | 10.0% | 15.6% |
| Return on tangible assets | 10.5% | 13.1% | 14.2% | 16.4% | 17.7% | 14.7% | 22.4% | 26.0% | 14.0% | 27.1% |
| Free cash flow margin | 37.2% | 35.7% | 43.1% | 38.9% | 42.1% | 45.7% | −9.6% | 39.1% | 37.0% | 28.6% |
| Income quality (OCF / net income) | 1.30 | 1.07 | 1.34 | 1.28 | 1.43 | 1.86 | 1.16 | 0.91 | 1.99 | 1.20 |
| Financial health | ||||||||||
| Total debt | $225,000 | $338,000 | $295,000 | $341,000 | $396,000 | $335,000 | $376,000 | — | $0 | $0 |
| Cash & short-term investments | $85.8M | $83.0M | $92.9M | $75.1M | $61.0M | $51.6M | $42.8M | $51.1M | $40.0M | $26.4M |
| Net debt | −$85.5M | −$82.6M | −$92.6M | −$74.7M | −$60.6M | −$51.3M | −$42.4M | −$51.1M | −$40.0M | −$26.4M |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
| Debt / assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
| Net debt / EBITDA | −5.00 | −4.21 | −3.74 | −2.69 | −2.30 | −2.45 | −1.73 | −2.36 | −1.83 | −1.39 |
| Current ratio | 37.62 | 25.64 | 22.56 | 15.09 | 19.53 | 16.42 | 15.92 | 11.58 | 9.32 | 11.54 |
| Quick ratio | 34.57 | 23.29 | 20.53 | 13.61 | 17.77 | 14.78 | 13.91 | 10.55 | 8.32 | 10.03 |
| Interest coverage | — | — | — | 22.8 | 4.5 | 1.9 | 2.5 | — | — | — |
| Working capital | $95.1M | $92.6M | $101.6M | $84.0M | $69.4M | $58.5M | $51.4M | $55.6M | $43.9M | $31.8M |
| Invested capital | $33.7M | $34.8M | $35.7M | $39.5M | $46.6M | $51.6M | $58.7M | $37.9M | $38.2M | $42.9M |
| Tangible asset value | $104.4M | $101.0M | $109.7M | $90.5M | $75.3M | $64.7M | $56.9M | $60.5M | $46.2M | $37.5M |
| Net current asset value | $94.5M | $91.2M | $99.1M | $80.3M | $64.7M | $53.3M | $46.2M | $50.1M | $34.6M | $27.5M |
| Graham number | $53.71 | $54.66 | $60.26 | $56.49 | $51.59 | $43.04 | $48.95 | $51.43 | $32.72 | $36.50 |
| Graham net-net per share | $27.50 | $24.36 | $25.59 | $20.31 | $16.29 | $13.31 | $10.99 | $12.28 | $8.21 | $6.29 |
| Capital allocation | ||||||||||
| Dividends paid | $4.0M | $4.3M | $4.3M | $3.2M | $11.5M | $4.1M | $4.1M | $4.0M | $3.0M | $3.9M |
| Share buybacks (net) | $8.4M | $20.0M | $2.5M | $2.5M | $7.0M | $7.0M | $398,000 | $1.2M | $2.9M | $2.9M |
| Dividend payout ratio | 35.3% | 30.7% | 25.7% | 19.2% | 77.5% | 38.1% | 27.9% | 21.7% | 34.7% | 32.3% |
| Dividends + buybacks / free cash flow | 86.2% | 166.0% | 31.3% | 27.8% | 89.3% | 57.5% | — | 31.8% | 37.9% | 60.3% |
| Capex / revenue | 1.0% | 0.6% | 1.3% | 1.6% | 1.1% | 2.0% | 45.9% | 1.0% | 3.9% | 8.4% |
| Capex / operating cash flow | 2.5% | 1.6% | 2.9% | 3.9% | 2.6% | 4.3% | 126.3% | 2.4% | 9.4% | 22.7% |
| Capex / depreciation | 0.12 | 0.08 | 0.10 | 0.12 | 0.08 | 0.12 | 3.13 | 0.14 | 0.58 | 1.17 |
| Stock-based compensation / revenue | 1.0% | 0.6% | 0.4% | 0.4% | 0.3% | 0.4% | 0.2% | 0.2% | 0.3% | 0.2% |
| R&D / revenue | 1.7% | 2.0% | 1.1% | 0.9% | 1.1% | 1.2% | 1.0% | 1.1% | 1.1% | 1.2% |
| SG&A / revenue | 25.8% | 13.6% | 25.3% | 22.8% | 23.5% | 26.9% | 24.2% | 17.0% | 16.8% | 17.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 36.1 | 33.4 | 32.4 | 37.2 | 34.4 | 38.3 | 33.8 | 32.9 | 30.1 | 36.1 |
| Days of inventory on hand | 163.9 | 200.3 | 166.3 | 140.0 | 129.0 | 144.1 | 129.0 | 123.9 | 118.9 | 102.2 |
| Days payables outstanding | 14.2 | 14.3 | 18.0 | 18.0 | 15.6 | 20.7 | 21.7 | 22.2 | 22.4 | 18.2 |
| Cash conversion cycle (days) | 185.8 | 219.4 | 180.8 | 159.3 | 147.7 | 161.7 | 141.1 | 134.7 | 126.7 | 120.1 |
| Receivables turnover | 10.12 | 10.93 | 11.25 | 9.80 | 10.62 | 9.54 | 10.79 | 11.08 | 12.12 | 10.11 |
| Payables turnover | 25.65 | 25.55 | 20.32 | 20.30 | 23.42 | 17.64 | 16.82 | 16.44 | 16.32 | 20.07 |
| Inventory turnover | 2.23 | 1.82 | 2.19 | 2.61 | 2.83 | 2.53 | 2.83 | 2.94 | 3.07 | 3.57 |
| Asset turnover | 0.31 | 0.32 | 0.39 | 0.44 | 0.43 | 0.38 | 0.45 | 0.44 | 0.49 | 0.50 |
| Average receivables | $3.8M | $3.7M | $4.5M | $5.3M | $4.6M | $4.4M | $4.3M | $3.8M | $3.4M | $3.9M |
| Average payables | $727,000 | $656,000 | $993,500 | $989,500 | $774,500 | $943,000 | $1.0M | $954,500 | $920,000 | $777,500 |
| Average inventory | $8.4M | $9.2M | $9.2M | $7.7M | $6.4M | $6.6M | $6.2M | $5.3M | $4.9M | $4.4M |
| Intangibles / total assets | 12.2% | 13.4% | 13.8% | 19.2% | 27.6% | 34.1% | 40.2% | 28.6% | 34.4% | 41.5% |
Computed from UTMD's annual financial statements (latest annual report filed March 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
UTMD valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Utah Medical Products traded at 16.1 times earnings, against a 10-year median of 22.4. Based on the latest twelve months, the trailing P/E is 22.7 and the forward P/E is 13.0. Utah Medical Products earned a return on equity of 9.5% and a return on invested capital of 26.6% in fiscal 2025. It ended the year with $0.2 million of debt and $85.8 million in cash and short-term investments, a net cash position of $85.5 million. It returned $12.3 million to shareholders: $4.0 million in dividends and $8.4 million in share buybacks, 86% of free cash flow. The share count fell 14.0% from 3.8M to 3.2M over 9 years.
See the UTMD income statement, the UTMD chart for price history, or the UTMD stock overview for the latest quote and news.
UTMD key metrics FAQ
What is Utah Medical Products's P/E ratio?
Utah Medical Products's trailing P/E ratio is 22.7 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 13.0. At the end of fiscal 2025 it was 16.1, compared with a 10-year median of 22.4.
What is Utah Medical Products's EV/EBITDA?
Utah Medical Products's enterprise value was 5.6 times EBITDA at the end of fiscal 2025 (enterprise value $95.8 million, EBITDA $17.1 million); the current EV/EBITDA is 11.9.
What is Utah Medical Products's return on equity?
Utah Medical Products's return on equity (ROE) was 9.5% in fiscal 2025: net income of $11.3 million on average shareholders' equity of $118.3 million.
What is Utah Medical Products's ROIC?
Utah Medical Products's return on invested capital was 26.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Utah Medical Products have?
Utah Medical Products had total debt of $0.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Utah Medical Products's dividend yield?
Utah Medical Products's forward dividend yield is 1.66%. Utah Medical Products paid $4.0 million in dividends in fiscal 2025 ($1.23 per share), a payout ratio of 35.3%.
Does Utah Medical Products buy back its shares?
Yes. Utah Medical Products spent $8.4 million on net share repurchases in fiscal 2025 Shares outstanding changed −7.5% over the year, to 3.2M..
What is Utah Medical Products's free cash flow yield?
Utah Medical Products generated $14.3 million of free cash flow in fiscal 2025, a free cash flow yield of 7.9% on its market value at year-end ($181.3 million).
What is Utah Medical Products's current ratio?
Utah Medical Products's current ratio was 37.62 at the end of fiscal 2025: current assets were 37.62 times current liabilities.